Thomas Harrison - Zynerba Pharmaceuticals Director Nominee
| ZYNEDelisted Stock | USD 1.30 0.04 3.17% |
Director
Dr. Thomas L. Harrison is an Independent Director of the company. Dr. Harrison served as a member of our Board since August 2015. Dr. Harrison is a noted author and speaker and since April 2013, has served as chairman emeritus of Diversified Agency Services, the world largest group of marketing services companies, and a division of Omnicom Group, Inc., or Omnicom. In 1987 he founded Harrison Star Business Group, a healthcare marketing agency that was acquired by Omnicom in 1992. From 1992 until 1997, he served as chairman of the Harrison Star Group and chairman of diversified healthcare communications for Omnicom. In 1997, Dr. Harrison was appointed president of diversified agency services, and in 1998 was named chairman and chief executive, serving until 2011. In 1980 he began his agency career at Rolf Werner Rosenthal, a midsized healthcare advertising agency. From 1974 until 1980 he served in sales and marketing roles at Pfizer, Inc. Dr. Harrison is a member of the Executive Committee of the Montefiore Hospital, a fellow of the New York Academy of Medicine, and governor of the New York Academy of Sciences where he sits on the Sackler Global Nutrition Committee. In 2013, Dr. Harrison became a board member of Dipexium Pharmaceuticals, Inc. and a board member of rVue Inc., a digital outofhome media company. In 2014, he was appointed to the boards of Social Growth Technologies, Inc. and of Fifth Street Asset Management Inc. where he serves as chairman of the audit committee. He previously served as a board member of each of the New York Chapter of the Arthritis Foundation, ePocrates, Inc., a publicly traded healthcare information company until its March 2013 acquisition by athenahealth, Inc., and The Morgans Hotel Group since 2015.
| Age | 69 |
| Tenure | 9 years |
| Phone | 484 581 7505 |
| Web | https://www.zynerba.com |
Zynerba Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4511) % which means that it has lost $0.4511 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8713) %, meaning that it created substantial loss on money invested by shareholders. Zynerba Pharmaceuticals' management efficiency ratios could be used to measure how well Zynerba Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 334.43 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Zynerba Pharmaceuticals has a current ratio of 6.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Zynerba Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Zynerba Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zynerba Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zynerba to invest in growth at high rates of return. When we think about Zynerba Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Judith Robertson | Durect | N/A | |
| Gerald Carlson | Phibro Animal Health | 75 | |
| Patricia Allen | Deciphera Pharmaceuticals LLC | 56 | |
| Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| John Freund | Collegium Pharmaceutical | 64 | |
| Susan Kelley | Deciphera Pharmaceuticals LLC | 63 | |
| David Hoffmann | Durect | 69 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Patrick Heron | Collegium Pharmaceutical | 44 | |
| Mary Malanoski | Phibro Animal Health | 61 | |
| Terrence Blaschke | Durect | 71 | |
| Christopher Alafi | Intracellular Th | 54 | |
| Gwen Melincoff | Collegium Pharmaceutical | 65 | |
| Eran Nadav | Collegium Pharmaceutical | 45 | |
| Jay Shepard | Durect | 56 | |
| Donal Carroll | FSD Pharma Class | 42 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 |
Zynerba Pharmaceuticals Leadership Team
Elected by the shareholders, the Zynerba Pharmaceuticals' board of directors comprises two types of representatives: Zynerba Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zynerba. The board's role is to monitor Zynerba Pharmaceuticals' management team and ensure that shareholders' interests are well served. Zynerba Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zynerba Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Baron, CFO, Treasurer | ||
| Ray Mannion, Vice President - Manufacturing | ||
| Albert II, Chief Sec | ||
| Daniel Kisner, Director Nominee | ||
| Brian Boyd, Vice President - Manufacturing | ||
| William Federici, Director Nominee | ||
| Liza Squires, Chief Medical Officer | ||
| Suzanne Hanlon, VP of HR, General Counsel and Secretary | ||
| Kenneth Moch, Director Nominee | ||
| Joseph Apostolico, VP HR | ||
| Thomas Harrison, Director Nominee | ||
| Brian Rosenberger, Vice President - Commercial | ||
| James Fickenscher, CFO, Vice President - Corporate Development | ||
| Nancy Tich, Vice President - Clinical | ||
| Warren Cooper, Director | ||
| Armando MBA, Chairman CEO | ||
| Armando Anido, Chairman and CEO | ||
| Cynthia Rask, Director Nominee | ||
| William Roberts, Vice President - Investor Relations and Corporate Communications | ||
| John Butler, Independent Director | ||
| Pamela Stephenson, Independent Director | ||
| Terri Sebree, President |
Zynerba Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zynerba Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Shares Owned By Insiders | 6.07 % | |||
| Shares Owned By Institutions | 12.12 % | |||
| Number Of Shares Shorted | 419.98 K | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zynerba Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zynerba Pharmaceuticals' short interest history, or implied volatility extrapolated from Zynerba Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |